

Expert Second Opinion: Optimizing the Use of Immunotherapy, MRD Assessment and Other Novel Approaches for Patients with Localized Colorectal Cancer —
Microlearning Activity 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following results best describes major efficacy findings from the Phase III ATOMIC study evaluating the addition of atezolizumab to standard chemotherapy for resected microsatellite instability-high (MSI-H)/mismatch repair-deficient Stage III colon cancer?**
 - Inferior disease-free survival (DFS) outcomes
 - A numerical but nonsignificant improvement in DFS
 - A significant improvement in DFS**
- 2. A 71-year-old patient with Stage III MSI-H sigmoid colon cancer, uncontrolled diabetes and Grade 2 neuropathy has come to you for a second opinion after receiving a recommendation of adjuvant therapy with atezolizumab and 5-FU without oxaliplatin. How would you respond?**
 - I agree with this recommendation
 - I do not agree with this recommendation**
- 3. Which of the following regimens best describes the adjuvant therapy administered on the experimental treatment arm of the Phase III ATOMIC study?**
 - Modified FOLFOX 6 (mFOLFOX6) for 6 months, followed by observation
 - Atezolizumab for 6 months, followed by observation
 - Atezolizumab + mFOLFOX6 for 6 months, followed by atezolizumab for 6 months**
 - Atezolizumab for 6 months, followed by atezolizumab + mFOLFOX6 for 6 months
- 4. A patient presents with Stage III colon cancer with a POLE mutation and undergoes RO resection. Which approach to adjuvant therapy would best reflect faculty recommendation in this activity?**
 - Surveillance
 - FOLFOX/CAPOX
 - FOLFOX/CAPOX + atezolizumab**